A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT05532163 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor's decision

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG: Natalizumab

Sponsor

Biogen